Drugs / SPR720
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05966688 | Aug 2023 → Jan 2024 | — | Spero Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05955586 | Aug 2023 → Feb 2024 | — | Spero Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03796910 | Dec 2018 → Sep 2019 | — | Spero Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05496374 | Dec 2022 → Oct 2024 | pulmonary non-tuberculous mycobacterial infection | Spero Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT04553406 | Dec 2020 → Jan 2021 | Mycobacterium avium complex disease, pulmonary non-tuberculous mycobacterial infection | Spero Therapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPR720 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04553406 ↗ |
| Action | Inhibit | “bacterial DNA gyrase (GyrB) inhibitor” PMID 34491803 ↗ Sep 2021 |
| Modality | Small molecule | “SPR720 (phosphate prodrug of SPR719) is a novel aminobenzimidazole bacterial DNA gyrase (GyrB) inhibitor” PMID 34491803 ↗ Sep 2021 |
| Route | Oral | “SPR720 administered orally in healthy volunteers” NCT03796910 ↗ |